HANGZHOU, China & NEWARK, Calif.–(BUSINESS WIRE)–First Patient Dosed in Atom’s Phase 2 Clinical Trial of Lingdolinurad (ABP-671) for Chronic Kidney Disease with Hyperuricemia

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.